Data / Drug companies / R J General Corporation
R J General Corporation: 21 products in the FDA NDC directory, labeler code 70264
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
R J General Corporation (labeler code 70264) lists 21 products in the FDA National Drug Code Directory, covering 14 finished drugs by generic name. By type: 21 over the counter drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on November 12, 2024.
The request: Watch R J General Corporation (FDA labeler code 70264): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 70264
- Products in commercial distribution
- 21
- Packages
- 21
- Finished drugs by generic name
- 14
- Prescription products
- 0
- Over the counter products
- 21
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- March 2, 2010
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 18 | 85.7% |
| New drug applications (NDA) | 3 | 14.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 21 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Ibuprofen | 5 | 190 |
| Acetaminophen | 3 | 214 |
| Diphenhydramine hydrochloride | 1 | 127 |
| Acetaminophen, caffeine, and pyrilamine maleate | 1 | 7 |
| Acetaminphen | 1 | 1 |
| Acetaminophen 250 mg and ibuprofen 125 mg | 1 | 1 |
| Naproxen sodium | 1 | 100 |
| Loratadine | 1 | 125 |
| Aspirin | 1 | 134 |
| Anhydrous citric acid, aspirin, and sodium bicarbonate | 1 | 3 |
| Acetaminophen, dextromethorphan hbr | 1 | 20 |
| Famotidine, calcium carbonate, and magnesium hydroxide | 1 | 5 |
| Calcium carbonate 750 mg | 1 | 3 |
| Acetaminophen, aspirin (nsaid), caffeine | 1 | 4 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 6 | 28.6% |
| Tablet, film coated | 6 | 28.6% |
| Tablet, coated | 3 | 14.3% |
| Capsule, liquid filled | 2 | 9.5% |
| Tablet, effervescent | 2 | 9.5% |
| Powder, for solution | 1 | 4.8% |
| Tablet, chewable | 1 | 4.8% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Theraflu Severe Cold Relief Daytime | 70264-047 | Powder, for solution | Over the counter monograph drugs | November 12, 2024 |
| Tums Antacid Chewy Bites | 70264-046 | Tablet | Over the counter monograph drugs | November 11, 2024 |
| Excedrin Extra Strength Headache | 70264-045 | Tablet, film coated | Over the counter monograph drugs | November 11, 2024 |
| Ibuprofen 200 mg | 70264-044 | Capsule, liquid filled | Over the counter monograph drugs | November 5, 2024 |
| Ibuprofen 200 mg | 70264-043 | Capsule, liquid filled | Over the counter monograph drugs | November 4, 2024 |
| Ibuprofen 200 mg | 70264-042 | Tablet, coated | Over the counter monograph drugs | November 1, 2024 |
| Ibuprofen 200 mg | 70264-041 | Tablet, coated | Over the counter monograph drugs | November 1, 2024 |
| Acetaminophen 250 mg and Ibuprofen 125 mg | 70264-040 | Tablet, film coated | Over the counter monograph drugs | October 30, 2024 |
| Alka-Seltzer Plus Severe Cold and Flu PowerFast Fizz | 70264-016 | Tablet, effervescent | Over the counter monograph drugs | March 16, 2023 |
| Benadryl Allergy | 70264-024 | Tablet, film coated | Over the counter monograph drugs | March 1, 2022 |
| Pepcid Complete | 70264-034 | Tablet, chewable | New drug applications (NDA) | January 9, 2022 |
| Motrin ib | 70264-029 | Tablet, film coated | Over the counter monograph drugs | May 1, 2021 |
| Tylenol pm extra strength | 70264-028 | Tablet, film coated | Over the counter monograph drugs | May 1, 2021 |
| Tylenol extra strength | 70264-027 | Tablet | Over the counter monograph drugs | May 1, 2021 |
| Tylenol sinus severe | 70264-026 | Tablet, coated | Over the counter monograph drugs | May 1, 2021 |
| Tylenol cold and flu | 70264-025 | Tablet, film coated | Over the counter monograph drugs | May 1, 2021 |
| Claritin | 70264-030 | Tablet | New drug applications (NDA) | March 1, 2021 |
| Bayer Genuine Aspirin | 70264-013 | Tablet | Over the counter monograph drugs | July 31, 2014 |
| Aleve | 70264-011 | Tablet | New drug applications (NDA) | February 26, 2014 |
| Midol complete | 70264-012 | Tablet | Over the counter monograph drugs | February 10, 2014 |
| Alka-Seltzer Original | 70264-014 | Tablet, effervescent | Over the counter monograph drugs | March 2, 2010 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.